ALNY vs. MTD: Alnylam Pharmaceuticals vs. Mettler-Toledo Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.
| Profile Item | ALNY | MTD |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Mettler-Toledo International Inc. |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 20.89 billion USD | 34.25 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2004 | November 14, 1997 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | MTD |
|---|---|---|
| Total Return (1Y) | -64.57% | 21.58% |
| Total Return (3Y, Annualized) | -1.58% | 19.54% |
| Total Return (5Y, Annualized) | -3.13% | 2.36% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | MTD |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 31.70% |
| Beta (5Y) | 0.45 | 1.15 |
| Max Drawdown (5Y) | -68.25% | -43.47% |
| Avg. Volume (3M) | 1.90M | 197.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | MTD |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 0.55 |
| Sortino Ratio (1Y) | -1.45 | 0.75 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Alnylam Pharmaceuticals (ALNY) earns 138.07% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- MTD
- --
Net Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Mettler-Toledo (MTD) at 22.25% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.25%
- MTD
- 22.25%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.70%
- Max
- 83.12%
- MTD
- 28.70%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | MTD |
|---|---|---|
| ROE (TTM) | 138.07% | -- |
| ROA (TTM) | 9.51% | 20.09% |
| Net Margin (TTM) | 52.85% | 22.25% |
| Operating Margin (TTM) | 23.72% | 28.70% |
| Gross Margin (TTM) | 77.28% | 59.16% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Mettler-Toledo (MTD) at 3.98% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | MTD |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 3.98% |
| Revenue Growth (3Y CAGR) | 52.98% | 0.90% |
| EPS Growth (YoY) | -- | 3.88% |
| EPS Growth (3Y CAGR) | -- | 3.06% |
Financial Strength
Current Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.10
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MTD
- 1.10
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but MTD is more stretched: Alnylam Pharmaceuticals (ALNY) at 0.83 sits in the higher-leverage quartile and Mettler-Toledo (MTD) at 26.06 is above its industry benchmark range.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.06
- MTD
- 26.06
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | MTD |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 1.10 |
| Debt / Equity (MRQ) | 0.83 | 26.06 |
| Net Debt / EBITDA | -0.57 | 1.58 |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | MTD |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Mettler-Toledo (MTD) at 37.38 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.38
- Max
- 85.34
- Q3
- 43.46
- MTD
- 37.38
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
- Max
- 58.18
- Q3
- 25.77
- MTD
- 8.16
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 5.79 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
442.71
- MTD
- 442.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | MTD |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 37.38 |
| P/S Ratio (TTM) | 4.17 | 8.16 |
| P/B Ratio (MRQ) | 5.79 | 442.71 |
| Free Cash Flow Yield (TTM) | 1.57% | 1.97% |